Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dermatomyositis.

J P Callen1

  • 1Division of Dermatology, University of Louisville, KY 40202, USA. Jefca@AOL.com

Lancet (London, England)
|January 1, 2000
PubMed
Summary
This summary is machine-generated.

Dermatomyositis, an idiopathic inflammatory myopathy, presents with distinct skin rashes and can be associated with cancer, especially in older adults. Research into myositis-specific antibodies may illuminate disease pathogenesis and improve treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-C1q antibodies in systemic lupus erythematosus.

Lupus·2014
Same author

Hypertrophic lupus erythematosus complicating long-standing systemic lupus erythematosus.

Lupus·2011
Same author

Drug-induced subacute cutaneous lupus erythematosus.

Lupus·2010
Same author

Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus.

Lupus·2004
Same author

Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis.

Clinical and experimental dermatology·2004
Same author

Update on the management of cutaneous lupus erythematosus.

The British journal of dermatology·2004
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Area of Science:

  • Rheumatology
  • Dermatology
  • Immunology

Background:

  • Dermatomyositis is an idiopathic inflammatory myopathy characterized by specific skin manifestations like heliotrope rash and Gottron's papules.
  • It is associated with an increased risk of malignancy, particularly ovarian cancer, and has a poorer prognosis in older patients.
  • A distinct childhood form exists, often complicated by calcinosis, and the disease can affect multiple organ systems beyond skin and muscle.

Purpose of the Study:

  • To summarize the key features, associations, and management of dermatomyositis.
  • To highlight the significance of myositis-specific antibodies in understanding the pathogenesis of inflammatory myopathies.
  • To discuss current treatment approaches for both systemic and cutaneous manifestations.

Main Methods:

Related Experiment Videos

  • Review of existing literature on dermatomyositis.
  • Analysis of clinical presentations, associations (e.g., cancer), and epidemiological data.
  • Evaluation of current therapeutic strategies, including corticosteroids, immunosuppressants, and novel agents.

Main Results:

  • Dermatomyositis exhibits characteristic cutaneous signs and systemic involvement, including potential cardiopulmonary and esophageal dysfunction.
  • A strong association with cancer, especially in older individuals, portends a poor prognosis.
  • Myositis-specific antibodies are emerging as important biomarkers, potentially aiding in understanding disease mechanisms.

Conclusions:

  • Dermatomyositis is a complex systemic autoimmune disease with significant cutaneous and potential malignant associations.
  • While systemic treatment often involves corticosteroids and immunosuppressants, managing cutaneous disease and understanding pathogenesis require further research.
  • Myositis-specific antibodies offer promising avenues for future diagnostic and therapeutic advancements in inflammatory myopathies.